NASDAQ:CFRX - ContraFect Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.5480 0.00 (0.00 %) (As of 01/21/2019 06:49 AM ET)Previous Close$0.5501Today's Range$0.5310 - $0.582552-Week Range$0.42 - $2.93Volume837,814 shsAverage Volume1.47 million shsMarket Capitalization$43.52 millionP/E Ratio-1.48Dividend YieldN/ABeta0.37 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York. Receive CFRX News and Ratings via Email Sign-up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CFRX Previous Symbol CUSIPN/A Webwww.contrafect.com Phone914-207-2300Debt Debt-to-Equity RatioN/A Current Ratio7.24 Quick Ratio7.24Price-To-Earnings Trailing P/E Ratio-1.48 Forward P/E Ratio-1.48 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book1.30Profitability EPS (Most Recent Fiscal Year)($0.37) Net Income$-15,510,000.00 Net MarginsN/A Return on Equity-345.89% Return on Assets-72.45%Miscellaneous Employees23 Outstanding Shares79,410,000Market Cap$43.52 million OptionableNot Optionable ContraFect (NASDAQ:CFRX) Frequently Asked Questions What is ContraFect's stock symbol? ContraFect trades on the NASDAQ under the ticker symbol "CFRX." How were ContraFect's earnings last quarter? ContraFect Corp (NASDAQ:CFRX) posted its earnings results on Thursday, November, 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.04. View ContraFect's Earnings History. When is ContraFect's next earnings date? ContraFect is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for ContraFect. What price target have analysts set for CFRX? 3 brokers have issued 12-month price objectives for ContraFect's shares. Their forecasts range from $2.80 to $2.80. On average, they expect ContraFect's stock price to reach $2.80 in the next twelve months. This suggests a possible upside of 410.9% from the stock's current price. View Analyst Price Targets for ContraFect. What is the consensus analysts' recommendation for ContraFect? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraFect. Has ContraFect been receiving favorable news coverage? News stories about CFRX stock have been trending somewhat negative on Monday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ContraFect earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. Are investors shorting ContraFect? ContraFect saw a increase in short interest in December. As of December 31st, there was short interest totalling 958,556 shares, an increase of 68.5% from the December 14th total of 568,940 shares. Based on an average daily trading volume, of 262,292 shares, the short-interest ratio is currently 3.7 days. Currently, 1.7% of the shares of the company are sold short. View ContraFect's Current Options Chain. Who are some of ContraFect's key competitors? Some companies that are related to ContraFect include Aquestive Therapeutics (AQST), VBI Vaccines (VBIV), ProMetic Life Sciences (PFSCF), Recro Pharma (REPH), Calithera Biosciences (CALA), Constellation Pharmaceuticals (CNST), Ocular Therapeutix (OCUL), AcelRx Pharmaceuticals (ACRX), Molecular Templates (MTEM), Nature's Sunshine Products (NATR), CytoDyn (CYDY), MOTIF BIO PLC/S (MTFB), Emisphere Technologies (EMIS), Poxel (PXXLF) and REDHILL BIOPHAR/S (RDHL). Who are ContraFect's key executives? ContraFect's management team includes the folowing people: Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 65)Mr. Michael Messinger, CFO & Chief Accounting Officer (Age 43)Ms. Nancy Dong, VP of Fin. & Admin. (Age 53)Ms. Natalie Bogdanos J.D., Gen. Counsel & Corp. Sec. (Age 49)Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 56) How do I buy shares of ContraFect? Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ContraFect's stock price today? One share of CFRX stock can currently be purchased for approximately $0.5480. How big of a company is ContraFect? ContraFect has a market capitalization of $43.52 million. The biotechnology company earns $-15,510,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. ContraFect employs 23 workers across the globe. What is ContraFect's official website? The official website for ContraFect is http://www.contrafect.com. How can I contact ContraFect? ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected] MarketBeat Community Rating for ContraFect (NASDAQ CFRX)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 155 (Vote Outperform)Underperform Votes: 125 (Vote Underperform)Total Votes: 280MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe CFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2019 by MarketBeat.com StaffFeatured Article: What are the benefits of momentum investing?